Recently, several new treatment proposals after summarizing a large number of clinical trial data have been put forward: including developing drugs to simultaneously or continuously target Aβ and Tau protein; non-biological targeted treatment strategies; or selecting mild cognitive impairment (MCI) patients or early AD patients as clinical trial subjects [35]. Here, MAPT is linked to Cognitive impairment.